Micafungina Reig Jofre

Micafungin Sodium, the active ingredient in Micafungina Reig Jofre, is an echinocandin presented as an intravenous solution for IV use. It is employed to treat invasive candidiasis, esophageal candidiasis, Candida auris infections, and to provide prophylaxis in hematopoietic stem‑cell transplantation.

GNH USA supplies Micafungina Reig Jofre as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for this parenteral product across global markets.

Micafungin Sodium is an echinocandin antifungal that inhibits fungal cell wall synthesis, making it effective for several serious Candida infections. - Invasive candidiasis: rapid clearance of bloodstream infection and reduction of mortality in adult and pediatric patients. - Esophageal candidiasis: promotes healing of mucosal lesions and alleviates dysphagia. - Candida auris infections: provides effective treatment against this multidrug‑resistant yeast. - Prophylaxis in hematopoietic stem‑cell transplantation: prevents invasive fungal disease during the neutropenic phase.

Micafungin Sodium may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Infusion‑related reactions: flushing, chills, or mild hypotension during administration. - Gastrointestinal discomfort: nausea, vomiting, or abdominal pain. - Elevated liver enzymes: transient increases in ALT or AST.

Serious or Rare Side Effects: - Severe hepatic injury: jaundice or hepatic failure requiring monitoring. - Anaphylaxis: acute allergic reaction with respiratory distress. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin blistering and detachment.

Prior to initiating Micafungin Sodium therapy, clinicians should consider several safety precautions to minimize risk. - Monitor liver function: obtain baseline and periodic ALT/AST levels during treatment. - Assess renal function: evaluate serum creatinine and adjust therapy if significant impairment occurs. - Check for hypersensitivity: discontinue immediately if signs of rash, angioedema, or anaphylaxis develop. - Use caution with concomitant nephrotoxic agents: increase monitoring for additive renal toxicity. - Adjust dose in severe hepatic impairment: consider reduced dosing or alternative therapy when indicated. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin Sodium can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Cyclosporine: micafungin may increase cyclosporine blood concentrations, risking nephrotoxicity. - Tacrolimus: co‑administration can raise tacrolimus levels, necessitating dose reduction. - Rifampin: strong enzyme induction may lower micafungin exposure, compromising antifungal activity.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole): may increase micafungin levels, requiring therapeutic monitoring. - Warfarin: potential alteration of INR, monitor coagulation parameters. - Statins (e.g., simvastatin): possible increased risk of myopathy, observe muscle symptoms. - Oral contraceptives: micafungin may reduce hormonal efficacy, advise alternative contraception.